DDInter740 DDInter1115
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. It is also considered as an active ingredient in over-the-counter products.
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Clozapine
Clozapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Arsenic trioxide
Arsenic trioxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Foscarnet
Foscarnet {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Sunitinib
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is downregulated by {v} (Compound) Methotrimeprazine
Methotrimeprazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Disopyramide
Disopyramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Entrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Flecainide {u} (Compound) downregulates {v} (Gene) RRM2
RRM2 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venlafaxine
Venlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Clozapine (Compound) and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Flecainide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Sunitinib (Compound) and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Flecainide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Flecainide (Compound) downregulates RRM2 (Gene) and RRM2 (Gene) is downregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate